(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2011 (24.02.2011)

PCT

(10) International Publication Number
WO 2011/022449 A1

(51) **International Patent Classification**:
A61K 31/454 (2006.01) ***A61P 29/00*** (2006.01)
C07D 401/06 (2006.01) ***A61P 19/02*** (2006.01)
A61P 11/00 (2006.01) ***A61P 1/00*** (2006.01)

(21) **International Application Number**:
PCT/US2010/045828

(22) **International Filing Date**:
18 August 2010 (18.08.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/235,482 20 August 2009 (20.08.2009) US
1050258 15 January 2010 (15.01.2010) FR

(71) **Applicant** *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **CHOI-SLEDESKI, Yong-Mi** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **GARDNER, Charles, J.** [US/US]; 14 Lenape Road, Flemington, New Jersey 08822 (US). **LIANG, Guyan** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **POLI, Gregory, B.** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **SHUM, Patrick, Wai-Kwok** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **STOKLOSA, Gregory, T.** [CA/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **ZHAO, Zhicheng** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(74) **Agents**: **BOLCSAK, James, W.** et al.; Sanofi-aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/022449 A1

(54) **Title**: DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1*H*-INDOL-3-YL]-METHANONES

(57) **Abstract**: The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of Claim 1. The present invention is directed also to the preparation of a compound of formula I.